KYNTRA BIO, INC.
Kyntra Bio, Inc. (Nasdaq: KYNB) is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia. The company rebranded from FibroGen, Inc. in January 2026 to reflect its strategic transformation and renewed focus on oncology and associated rare disease indications. More information is… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What KYNTRA BIO, INC. does
In the company’s own words
Kyntra Bio, Inc. (Nasdaq: KYNB) is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia. The company rebranded from FibroGen, Inc. in January 2026 to reflect its strategic transformation and renewed focus on oncology and associated rare disease indications. More information is available at www.kyntrabio.com.
The company's primary development pipeline centers on two major programs. FG-3246 is a potential first-in-class antibody-drug conjugate targeting CD46 for treating metastatic castration-resistant prostate cancer in the post-ARPI, pre-chemotherapy setting. This program includes FG-3180, a companion CD46-targeted positron emission tomography imaging agent designed for patient selection and biomarker assessment. Kyntra Bio initiated a Phase 2 monotherapy dose optimization study of FG-3246 in the third quarter of 2025, with interim results expected in the second half of 2026. The company also maintains development rights to roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, for treating anemia associated with lower-risk myelodysplastic syndromes in the United States, Canada, Mexico, and select other markets.
Roxadustat is currently approved in Europe, Japan, China, and numerous other countries for treating anemia in chronic kidney disease patients. In August 2025, Kyntra Bio closed the sale of its China operations to AstraZeneca Treasury Limited for total consideration of $220.4 million, comprising $85.0 million in enterprise value and $135.4 million in net cash held in China. This transaction included all roxadustat assets in China. Astellas Pharma Inc. commercializes roxadustat in Europe and Japan under separate development and commercialization license agreements.
The company's revenue has been generated primarily through collaboration agreements with Astellas and AstraZeneca for roxadustat development and commercialization. Kyntra Bio holds an exclusive option agreement with Fortis Therapeutics to acquire the company and its FG-3246 technology, with the option period extending through December 31, 2027. The company manufactures roxadustat through third-party contract manufacturers, including Shanghai SynTheAll Pharmaceutical Co., Ltd. for active pharmaceutical ingredient production and Catalent Pharma Solutions for drug product manufacturing.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 921299
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns KYNTRA BIO, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · KYNTRA BIO, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do KYNTRA BIO, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of KYNTRA BIO, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in KYNTRA BIO, INC.'s last four quarterly filings that the numbers alone won't show?”